The Joe Rogan Experience #2469 – Brigham Buhler

Date: March 18, 2026
Host: Joe Rogan
Guest: Brigham Buhler

Episode Overview

This episode focuses on the evolving landscape of healthcare—specifically peptides, hormone therapies, stem cell innovations, the regulatory hurdles facing these advancements, and the challenges from entrenched pharmaceutical interests. Brigham Buhler, founder of Ways2Well, returns to discuss recent progress and setbacks in the movement for personalized, preventive, and longevity-centered medicine. The conversation is candid, wide-ranging, and dives deep into science, policy, and ethics, all with a sense of urgency about fixing a deeply dysfunctional healthcare system.

Key Discussion Points & Insights

1. FDA Regulation, Peptides, and the State of Health Policy

• Recent Developments in Peptide Regulation

  • Peptides were previously classified as "dangerous" under a prior FDA administration, with little transparency or scientific basis (FOIA requests for safety data were ignored).
  • Buhler expresses optimism about current efforts to reverse these restrictions under new FDA leadership and Secretary Kennedy’s direction.
  • "[I submitted] 17 FOIA requests, 17 to the FDA. They have never once responded to a single FOIA request. ... To being able to at least have a seat at the table in a voice is pretty revolutionary." (02:10) — Brigham Buhler

• Dogma vs. Progress in Medicine

  • Much of the resistance to peptide therapy (and hormone therapy) is rooted in outdated studies and medical dogma rather than new evidence.
  • "What he's saying is dogma and that medicine is so worried about defending their principles ... they're ignoring at times science." (04:54) — Buhler, referencing Dr. Marty Makary's book Blind Spot

• Testosterone & Hormone Therapy Myths

  • The fear that testosterone therapy causes prostate cancer is traced to a 1930s study with an absurdly small sample size; more recent evidence refutes this risk.
  • "[There is] not one single study that correlates testosterone therapy to prostate cancer." (07:42) — Buhler

• Politics, Lobbying & Pharma Influence

  • The pharmaceutical industry lobbies aggressively against compounding pharmacies, especially around GLP-1 weight loss drugs.
  • "[Big Pharma says] ... they're making our drugs, they're violating our patent. If your concern is that these companies didn't get the juice worth the squeeze from the patent, Eli Lilly 7x the value of their company, they're worth $800 billion." (22:53) — Buhler

2. The Cash-Pay & Preventative Medicine Model

• Problems With Traditional Insurance-Based Healthcare

  • U.S. healthcare is described as being reactive—focused on treating catastrophic events rather than preventing chronic disease.
  • "We are absolutely an abysmal failure at preventing chronic disease and driving healthspan." (33:21) — Buhler

• Cash Pay as the Innovation Engine

  • Buhler advocates for a parallel, affordable cash-pay system that allows for patient autonomy, personalized medicine, and proactive care—outside insurance and government payer models.
  • "The only way to do that is to get proactive and predictive and personalized. And this entire ecosystem is just not built to do that." (33:48) — Buhler

• Challenges and Dangers of the Black & Gray Market

  • Over-regulation or unclear pathways have driven patients to unregulated suppliers—often with dubious products and real safety concerns.
  • "Four out of five peptides being filled are being filled through gray or black market solution. ... There is no clinician in the chain of custody." (61:18) — Buhler

3. GLP-1s, Compounding, and the Struggle for Access

• GLP-1 Weight Loss Drugs—A Double-Edged Sword

  • Much controversy centers on GLP-1 peptides: Big Pharma wants exclusivity, while compounding pharmacies argue for patient-specific dosing flexibility and access.
  • "Catastrophic muscle wasting" can occur without proper titration (dosing flexibility), often available only through compounding (56:40–57:04).
  • Regulatory changes have sharply curtailed compounding’s share of the market—even though, as Buhler notes, this is a "rounding error" for enormous drug companies.

• Bad-Actor Market Strategies

  • Some telemedicine and tech-first companies (e.g., Hims) are called out for flouting the rules, marketing unapproved treatments, and then leveraging backlash to ink exclusive deals with Big Pharma, harming small compounding pharmacies and patient choice.
  • "This is the equivalent to somebody coming into your living room and taking a dump on your dining room table." (46:29) — Buhler on illegal marketing practices

4. The Promise and Complexity of Stem Cells & Muse Cells

• Traditional Stem Cells vs. Muse Cells

  • Traditional MSCs (mesenchymal stem cells) are safe but cannot regenerate tissue in a meaningful way in the body; they simply create an environment for healing.
  • Muse cells, a rare sub-phenotype discovered by Dr. Mari Dezawa, are pluripotent, stress-enduring, highly targeted, and can differentiate into any cell type.
  • "Mus have a 15-30% engraftment rate ... when administered intravenously to pass the lungs and make it to the site of inflammation and damage." (108:51) — Buhler

• Real-World Cases & Outcomes

  • Muse cells are already in use overseas, with reports of "miraculous" recoveries, e.g., comatose patients regaining function and children with birth injuries developing normally.
  • "[A] kid who had been comatose ... they treat this kid with intravenous Muse cells and his brain function has come back." (127:34) — Buhler

• Regulatory Pathways & State Initiatives

  • Texas, Florida, Arizona, and Utah are building state-level pathways for personalized and regenerative medicine, aiming to become "medical tourism" destinations.
  • The goal is a dual system where federal and state frameworks allow for safe, accessible longevity therapies.

5. Data, AI, and Genetic Sequencing: Medicine’s Next Leap

• Integrating Diagnostics, AI & Genomics

  • Ways2Well is building AI-powered platforms to interpret blood work, VO2 max, DEXA, and—eventually—full genetic sequencing (20,000 genes) to offer truly predictive, individualized care.
  • "We're going to be able to scale concierge medicine ... for pennies on the dollar." (91:13) — Buhler

• Genetic Markers & Athletic Performance

  • Examples: MMA athletes and arm-wrestlers who are genetic outliers (denser bones, more resilient tendons) are identified using modern sequencing.
  • Insights can inform risk (e.g., tendency for staph infections), tailor prevention, and drive new therapies, including futuristic gene-editing possibilities.

6. The Case for Patient Autonomy

• Why Cash-Pay, Concierge, and Patient-Driven Models Matter

  • "In the insurance model, ... you got to go to this doctor because they're within your plan. ... The patient's going to have the same price, because that price is controlled by the PBM. ... My goal is to help you drive healthspan and monetize your health." (85:22) — Buhler

• The Importance of Restoring a Doctor-Patient Relationship

  • The future of medicine, Buhler argues, must unite technology and data with empathy, seeing the clinician-patient relationship as central.

• A Vision Beyond Drugs

  • Future therapies might work at the genetic or cellular level—outpacing today's petrochemical-driven, side-effect-prone pharmaceutical industry.

Notable Quotes & Memorable Moments

• On Medical Dogma:

  • "Myth becomes reality, right? And misnomer can be adopted. ... and it becomes urban legend, which is crazy to think." (12:23) — Buhler

• On Chronic Disease & the System’s Failure:

  • "We are the wealthiest country in the world. We are the sickest country in the world. We've never had more money. We've never been more sick." (79:49) — Rogan

• On Regulation and Pharma Power:

  • "If your concern is that these companies didn't get the juice worth the squeeze from the patent, Eli Lilly 7x the value of their company ... The money was made 50,000 times over." (22:53) — Buhler

• On Patient Sovereignty:

  • "My message ... is to build a life raft. ... and allow a patient to have sovereignty and autonomy over their health." (52:22) — Buhler

• On Data-Driven Personalized Health:

  • "Imagine when I get to a point ... we're tracking all these data analytics. We know that every man with a gene marker of P452 who went on testosterone saw a market improvement in REM sleep." (86:28) — Buhler

• On Muse Cells:

  • "These mu cells differentiate, so they literally are regenerative cells that become the broken cell that allow your body to heal." (132:59) — Buhler

Timestamps for Important Segments

• 03:20: The FDA’s stonewalling on peptide decisions
• 06:41: Testosterone therapy and the outdated cancer risk myth
• 13:08: The persistence of medical dogma and urban legends
• 18:20: The power and influence of pharmaceutical lobbying
• 31:34: Hypothetical: If only pharma made peptides
• 33:11: U.S. healthcare’s failure to prevent chronic disease
• 46:29: Hims’ marketing malpractices and repercussions
• 56:40: Titration of GLP-1s and the role of compounding
• 61:18: The black/gray market for peptides
• 69:46: Rational regulatory approaches to stem cells and peptides
• 85:22: The insurer-controlled prescription and pharmacy lock-in
• 89:09: Building integrated, data-driven health tracking platforms
• 108:51–117:00: Muse cell discovery, differentiation, safety, and real-world impact
• 127:34: Life-changing cases overseas with Muse cell therapy
• 138:08: Plasmapheresis as a longevity tool

Episode Highlights & Tone

• Tone: Candid, passionate, sometimes frustrated but hopeful, deeply skeptical of authority when earned, and relentlessly focused on data and real-world outcomes.
• Brigham Buhler’s Approach: Blends clinical experience, scientific skepticism, and a palpable drive to reform how Americans approach their health.
• Joe Rogan’s Role: Amplifies patient perspective, pushes for clarity and accountability, and challenges entrenched industry behaviors with humor and bluntness.

Summary Takeaways

This episode is a comprehensive case study in the battle between innovation and institutional inertia in healthcare. Buhler and Rogan argue that dogma, profit motives, and systemic barriers continue to stall promising therapies—from peptides to advanced stem cells—while regulators struggle to keep up and patients seek out riskier options. They champion a future in which the best diagnostic and therapeutic science is available, affordable, guided by data and human connection, and ultimately operates in a framework that prioritizes patient sovereignty and healthspan over chronic sickness and profit. The episode is a clarion call for both grassroots action and systemic reform.

For Listeners: Why This Matters

If you’re frustrated by conventional medicine, curious about biohacking, or seeking to understand why progress in health feels slow—this episode will both educate and energize you. It’s about reclaiming your agency, staying skeptical, and daring to imagine a future where American health actually lives up to its cost and potential.